Identification of chrysoplenetin from vitex negundo as a potential cytotoxic agent against PANC-1 and a panel of 39 human cancer cell lines (JFCR-39)

Phytotherapy Research

Volumn 25, Issue 12, 2011, Pages 1770-1775

  Awale, Suresh ^a   Linn, Thein Zaw ^a,b   Li, Feng ^a   Tezuka, Yasuhiro ^a   Myint, Aung ^b   Tomida, Akihiro ^c   Yamori, Takao ^c   Esumi, Hiroyasu ^d   Kadota, Shigetoshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b University of Traditional Medicine   (Myanmar)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

chrysoplenetin; chrysosplenol D; COMPARE; JFCR 39; PANC 1 human pancreatic cancer; Vitex negundo

Indexed keywords

CHRYSOPLENETIN; CHRYSOPLENOL D; CYTOTOXIC AGENT; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; VINCRISTINE; VITEX NEGUNDO EXTRACT;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; LUNG CANCER; MELANOMA; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; STOMACH CANCER;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; HUMANS; PANCREATIC NEOPLASMS; PLANT EXTRACTS; PLANTS, MEDICINAL; VITEX;

VITEX NEGUNDO;

EID: 82155161816     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3441     Document Type: Article

References (20)

1. Awale S, Lu J, Kalauni SK, et al,. 2006a. Identification of arctigenin as an antitumor agent having the ability to eliminate the tolerance of cancer cells to nutrient starvation. Cancer Res 66: 1751-1757. (Pubitemid 43259960)
2. Awale S, Nakashima EMN, Kalauni SK, et al,. 2006b. Angelmarin, a novel anti-cancer agent able to eliminate the tolerance of cancer cells to nutrient starvation. Bioorg Med Chem Lett 16: 581-583. (Pubitemid 43014840)
3. Chung HW, Bang SM, Park SW, et al,. 2004. A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 60: 1494-1501. (Pubitemid 39601866)
4. Dan S, Okamura M, Seki M, et al,. 2010. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res 70: 4982-4994.
5. Dan S, Tsunoda T, Kitahara O, et al,. 2002. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62: 1139-1147. (Pubitemid 34160300)
6. Diaz F, Chavez D, Lee D, et al,. 2003. Cytotoxic flavone analogues of vitexicarpin, a constituent of the leaves of Vitex negundo. J Nat Prod 66: 865-867. (Pubitemid 36782101)
7. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H,. 2000. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res 60: 6201-6207.
8. Lai-King S, Brown GD,. 1998. Three sesquiterpenes from Artemisia annua. Phytochemistry 48: 1207-1211. (Pubitemid 28317184)
9. Li D, Xie K, Wolff R, Abbruzzese JL,. 2004. Pancreatic cancer. Lancet 363: 1049-1057. (Pubitemid 38410779)
10. Nakatsu N, Nakamura T, Yamazaki K, et al,. 2007. Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines. Mol Pharmacol 72: 1171-1180. (Pubitemid 350012591)
11. Paull KD, Shoemaker RH, Hodes L, et al,. 1989. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Nat Cancer Inst 81: 1088-1092. (Pubitemid 19175145)
12. Rubinstein LV, Shoemaker RH, Paull KD, et al,. 1990. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Nat Cancer Inst 82: 1113-1118. (Pubitemid 20213251)
13. Strong K, Mathers C, Epping-Jordan J, Resnikoff S, Ullrich A,. 2008. Preventing cancer through tobacco and infection control: how many lives can we save in the next 10 years? Eur J Cancer Prev 17: 153-161. (Pubitemid 351301627)
14. Van Cutsem E, Vervenne WL, Bennouna J, et al,. 2009. Phase III Trial of Bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27: 2231-2237.
15. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S,. 2007. Bioactive secondary metabolites from Boesenbergia pandurata of Myanmar and their preferential cytotoxicity against human pancreatic cancer PANC-1 cell line in nutrient-deprived medium. J Nat Prod 70: 1582-1587. (Pubitemid 350155407)
16. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S,. 2008a. Novel anticancer agents, kayeassamins A and B from the flower of Kayea assamica of Myanmar. Bioorg Med Chem Lett 18: 4688-4691.
17. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S,. 2008b. Novel anticancer agents, kayeassamins C-I from the flower of Kayea assamica of Myanmar. Bioorg Med Chem 16: 8653-8660.
18. Win NN, Awale S, Esumi H, Tezuka Y, Kadota S,. 2008c. Panduratins D-I, novel secondary metabolites from rhizomes of Boesenbergia pandurata. Chem Pharm Bull 56: 491-496. (Pubitemid 351520132)
19. Yaguchi S-I, Fukui Y, Koshimizu I, et al,. 2006. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst 98: 545-556. (Pubitemid 43898818)
20. Yamori T, Matsunaga A, Sato S, et al,. 1999. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 59: 4042-4049. (Pubitemid 29393575)